Get the Stockscreener App
16.27
0.06%
-0.01
After Hours:
16.58
0.31
+1.91%
Myriad Genetics Inc Stock (MYGN) Latest News
MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View - MSN
Fisher Asset Management LLC Boosts Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Why Myriad Genetics, Inc. Shares Soared - AOL
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives $27.36 Average PT from Analysts - MarketBeat
Myriad Genetics settles shareholder lawsuits, agrees to reforms - Investing.com India
Myriad Genetics Settles Shareholder Lawsuits with Reforms - TipRanks
Myriad Genetics settles shareholder lawsuits, agrees to reforms By Investing.com - Investing.com UK
Myriad Genetics Reforms Corporate Governance to Settle Lawsuits - Bloomberg Law
Myriad Genetics, Inc. (NASDAQ:MYGN) Stock Position Lifted by Loomis Sayles & Co. L P - MarketBeat
MYGN Stock Up on Integration of HRD Platform Into Illumina's TSO 500 v2 - MSN
This Week in Chancery Court: Myriad Genetics Settlement Ruling - Bloomberg Law
Connor Clark & Lunn Investment Management Ltd. Boosts Stock Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
(MYGN) Trading Report - Stock Traders Daily
Natixis Advisors LLC Buys 44,646 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Gene Panel Market to Surpass USD 11.75 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.
Clinical Oncology Next Generation Sequencing (NGS) Market - openPR
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2 - The Manila Times
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2 - GlobeNewswire
Myriad Genetics Expands Illumina Partnership, Integrates Key Cancer Testing Technology | MYGN Stock News - StockTitan
MYGN Stock Might Gain From SneakPeek Availability in Retail Stores - MSN
Myriad Genetics (NASDAQ:MYGN) Downgraded to "Hold" Rating by StockNews.com - MarketBeat
Breast Cancer Screening and Diagnostic Techniques Market - openPR
Myriad Genetics (NASDAQ:MYGN) Reaches New 12-Month Low Following Analyst Downgrade - MarketBeat
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy - GlobeNewswire
Myriad Genetics Launches Industry's First 8-Week Prenatal DNA Screen | MYGN Stock News - StockTitan
Myriad Genetics price target lowered to $21 from $32 at Morgan Stanley - Yahoo Finance
Myriad Genetics (NASDAQ:MYGN) Given New $21.00 Price Target at Morgan Stanley - MarketBeat
State of New Jersey Common Pension Fund D Acquires New Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC - GlobeNewswire
Simplify Asset Management Inc. Buys Shares of 173,626 Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Predictive Genetic Testing & Consumer/Wellness Genomics Market Projected to Reach USD 17.66 Billion by 2032, Growing at a 13.33% CAGR – SNS Insider - GlobeNewswire
Predictive Genetic Testing & Consumer/Wellness Genomics - GlobeNewswire
Long Term Trading Analysis for (MYGN) - Stock Traders Daily
Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch - The Manila Times
Minimal Residual Disease Testing Market Share, Growth Drivers, - openPR
Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price - Simply Wall St
Myriad Genetics stock hits 52-week low at $16.6 amid market shifts - Investing.com Australia
Myriad Genetics Inc (MYGN) Shares Gap Down to $16.76 on Nov 12 - GuruFocus.com
Myriad Genetics: Healthcare Marketing Impact Awards 2024 - Modern Healthcare
How Myriad Genetics helped address the gap in genetic testing among women - Ad Age
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Investors to Learn More About the Investigation - AccessWire
Myriad Genetics, Inc. (NASDAQ:MYGN) Q3 2024 Earnings Call Transcript - Insider Monkey
Piper Sandler Has Lowered Expectations for Myriad Genetics (NASDAQ:MYGN) Stock Price - MarketBeat
U.S. Women Health Laboratory Testing Market to Witness - openPR
Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Myriad Genetics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Myriad Genetics Inc (MYGN) Quarterly 10-Q Report - Quartzy
Myriad Genetics Inc (MYGN) Q3 2024 Earnings Call Highlights: Str - GuruFocus.com
Myriad Genetics Inc (MYGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Policy ... - Yahoo Finance
Myriad Genetics earnings beat by $0.04, revenue topped estimates - Investing.com Canada
0.41%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):